Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs.
Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain.
Neuropathic pain represents 18% of chronic pain cases and impacts 100 - 560 million people globally. Akelos focuses on three key segments: diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia.
The global market was estimated at $5.4 billion in 2016, and is projected to reach $8.3 billion by 2024.
Opioids are routinely prescribed for neuropathic pain, but their effectiveness is limited. Less than 35% of patients achieving meaningful benefits from current therapeutic approaches. In addition, opioid treatment poses substantial safety risks. We believe it's time to pursue safe and effective treatments.
An estimated 20 million people in the United States live with chronic neuropathic pain, for which opioid medication is a common treatment. The opioid epidemic was cited as a causal factor in more than 50,000 deaths in 2015 alone; The problem is global.
Akelos is a collaboration founded to develop opioid drug alternatives.
Researchers at Weill Cornell University and Columbia University
have developed novel compounds for the treatment of neuropathic
pain, resulting in intellectual property that is jointly owned by
Cornell and Columbia. Akelos has licensed this intellectual
property and is developing a treatment for neuropathic pain using
the novel compounds.
"The unprecedented opioid epidemic has made it all the more
important to develop new medications that relieve pain without the
addictive qualities that can lead to dependency. Our medical
research, led by Dr. Goldstein, is a critical step to realizing
the goal of an opioid alternative."
- Dr. Steven Fox, Chairman of Akelos Inc.
Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti- hyperalgesic drug...
View MoreIn a just published study in the journal Nature, three research teams identify the binding site in human HCN1 (hHCN1) ion channel...
View MoreAkelos Inc. Appoints Dr. Scott L. Dax to Scientific Advisory Board, Furthering Research and Development of Non-Opioid Solutions for Chronic...
View MoreThis is an incredible story of Dr Steve Fox bringing together some of the best minds in the country to change the world of teeth hygiene forever. Raising $70 Million...
View MoreAkelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat...
View MoreIn this episode, we delve into Dr. Fox’s groundbreaking work in dentistry, where he transformed the industry with innovative oral...
View MorePotential Neuropathic Pain Treatment Shows Promise in Preclinical Tests. A non-opioid designer molecule for treating chronic neuropathic ...
NEW YORK, NEW YORK, UNITED STATES, February 14, 2023 /EINPresswire.com/ -- Akelos Inc., announces that the United States Patent and Trademark Office has allowed a patent application (17/254,787). . .
View MoreNEW YORK, February 1, 2023 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat ...
Akelos Inc. has been awarded a Phase I/II Fast-Track Small Business Technology Transfer (STTR) grant. . .
Akelos is a new biopharmaceutical company focused on the translation of innovative science into treatment.
NEW YORK, February 5, 2021 (Newswire.com) - Dr. Peter Goldstein, scientific co-founder . . .
. . .These results clearly validate the lead molecule as an effective approach to relieving neuropathic pain, which is notoriously difficult to treat. That it is a non-opiate only enhances its usefulness. . .
Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic . . .
NEW YORK, November 18, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid . . .
NEW YORK, June 17, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid . . .
NEW YORK, April 29, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing ...
NEW YORK, April 25, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a ...
NEW YORK, February 25, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic ...
NEW YORK, April 4, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and ...
NEW YORK, February 11, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat ...
NEW YORK, March 11, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug ...
NEW YORK, March 27, 2019 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel...
NEW YORK, November 26, 2018 (Newswire.com) - Akelos Inc., a biopharmaceutical company focused on the development of new drugs for neuropathic pain announced ...
NEW YORK, November 5, 2018 (Newswire.com) - Akelos Inc., a new biopharmaceutical company focused on the translation of innovative science into treatment ...
NEW YORK, May 21, 2019 (Newswire.com) - Akelos’s application to register its trademark AKELOS took another step...